Table 1

Characteristics of patients with juvenile idiopathic arthritis (JIA)

Sex Age at onset (years) Disease duration (years) JIA suptype1-150 Previous DMARD1-151 Concomitant medication Current treatment
1Male77VI MTX,SUL, AURNSAIDs, MTX, prednisone 7.5 mgNSAIDs, MTX, prednisone 7.5 mg
2Female44II MTX,SUL, AURNSAIDs, MTX, prednisone 5 mgNSAIDs, MTX, prednisone 2.5 mg/48 h
3Female32.5II MTX,SUL,NSAIDs, MTX, prednisone 5 mgNSAIDs, MTX, prednisone 2.5 mg/48 h
4Female2.54IVb MTX,SUL, AUR, ivIGGNSAIDs, MTX, prednisone 2.5 mgNSAIDs, MTX,
5Female74III MTX,SUL, AURNSAIDs, MTX, prednisone 5 mgNSAIDs, MTX, prednisone 2.5 mg/48 h
6Female38IVb MTX,SUL, AUR, ivIGG, CHLNSAIDs, MTX, prednisone 2.5 mgNSAIDs, MTX,
7Male92.5I MTX, AZA, CSA, pulse prednisolone, ivIGGNSAIDs, MTX, prednisone 7.5 mg,
  • 1-150 JIA subtypes: I, systemic onset; II, seronegative polyarticular onset; III, seropositive polyarticular onset; IV, oligoarticular onset, IVb, oligoarticular onset and polyarticular course; VI, psoriasis and arthritis.7

  • 1-151 DMARD = disease modifying drugs: MTX = methotrexate; SUL = sulfasalazine; AUR = injectable gold salts; CHL = chlorambucil; ivIGG = high dose intravenous immunoglobulins; CSA = cyclosporin A; AZA = azathioprine; NSAIDs = non-steroidal anti-inflammatory drugs. DMARDs used directly before entry to the study are printed in bold. The dose of methotrexate was 10–15 mg/m2 body surface per week.